Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Con...( Comprehensive Data Provide Initia...),Health

Comprehensive Data Provide Initial Proof of Concept Across Multiple

Applications in the Hospital Setting

Poster Presentation Number: 2032

Presenting Author: Dr. Mark Chan

MUNICH, Germany, Sept. 2 /PRNewswire/ -- Regado Biosciences, Inc. announced today the presentation of comprehensive results from Phase Ia, Ib and Ic studies of the Company's REG1 Anticoagulation System at the European Society of Cardiology's Congress 2008, currently being held in Munich, Germany. REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which binds to and neutralizes RB006.

Results from the three Phase I studies showed RB006 inhibited the activity of factor IXa, a protein essential to blood clotting, and RB007 rapidly, safely and specifically reversed the activity of RB006. Results from the Phase Ic study further support the potential for RB007 to reverse the anticoagulant effect of RB006 in a graded fashion either completely or partially, depending on the dose of RB007. Detailed findings included:

-- Escalating doses of RB006 achieved a dose-dependent increase in

pharmacodynamic activity in healthy subjects, prolonging the activated

partial thromboplastin time (aPTT), a measure of the blood's ability to

clot.

-- This response also was seen in patients with stable coronary artery

disease, thereby confirming pharmacodynamic reproducibility in the

target patient population.

-- Escalating doses of RB007 rapidly achieved a dose-dependent decrease in

aPTT in patients previously dosed with RB006. Complete inhibition of

RB006 was shown within 1-5 minutes of administration of sufficient

doses of RB007.

-- No major bleeding, allergic or thrombotic events occurred in any of the

studies. The majority of event
'/>"/>